

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司 (the “**Company**”) dated 19 April 2017 (the “**Announcement**”) in relation to the proposed disposal of the entire equity interest of Weixing by the Group. Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board would like to clarify that, the date of the AGM as set out in the section headed “Definitions” at page 8 of the Announcement, should be 23 June 2017 instead of 13 June 2017.

Save for the clarification stated above, all the information in the Announcement remains unchanged.

By order of the Board

Livzon Pharmaceutical Group Inc. *

麗珠醫藥集團股份有限公司

Yang Liang

Company Secretary

Zhuhai, China

27 April 2017

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Yang Daihong (Vice President); the Non-executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*